The past decade had witnessed frequent breaks in therapeutic development targeting LRP5 signaling, namely, the anti-DKK1 and anti-sclerostin molecules in the treatment of postmenopausal osteoporosis (Li et al., 2005; Niehrs, 2006; Williams, 2017). The gene discussed is SOST; the disease is postmenopausal osteoporosis.